Cargando…

Net Clinical Benefit of Direct Oral Anticoagulants in Patients With Cancer and Venous Thromboembolism: A Systematic Review and Trade-Off Analysis

Background: Venous thromboembolism (VTE) is highly prevalent in cancer patients. Recent guidelines recommend considering direct oral anticoagulants (DOACs) for the treatment of cancer-associated thrombosis (CAT). However, direct head-to-head comparisons among DOACs are lacking, and almost no net cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Yi-Dan, Ding, Zheng, Pan, Mang-Mang, Xia, Qing, Cui, Jiu-Jie, Wang, Li-Wei, Zhang, Chi, Gu, Zhi-Chun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693545/ https://www.ncbi.nlm.nih.gov/pubmed/33304929 http://dx.doi.org/10.3389/fcvm.2020.586020

Ejemplares similares

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Patients With Cancer: A Systematic Review and Trade-Off Analysis From 9 Randomized Controlled Trials
por: Yan, Yi-Dan, et al.
Publicado: (2018)

Global Research Hotspots in Venous Thromboembolism Anticoagulation: A Knowledge-Map Analysis from 2012 to 2021
por: Wang, Jia, et al.
Publicado: (2023)

Incidence of Venous Thromboembolism in Hospitalized Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis
por: Zhang, Chi, et al.
Publicado: (2020)

Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016)

Association Between Anticoagulation Outcomes and Venous Thromboembolism History in Chronic Thromboembolic Pulmonary Hypertension
por: Zhu, Yong-Jian, et al.
Publicado: (2021)

Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2021)

Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants
por: Qureshi, Waqas, et al.
Publicado: (2016)

Patient Characteristics and Preferences Regarding Anticoagulant Treatment in Venous Thromboembolic Disease
por: Lanéelle, Damien, et al.
Publicado: (2021)

Factor XI, a potential target for anticoagulation therapy for venous thromboembolism
por: Li, Tingting, et al.
Publicado: (2022)

Direct Oral Anticoagulants and Travel-related Venous Thromboembolism
por: Chamnanchanunt, Supat, et al.
Publicado: (2018)

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan
por: Nakamura, Mashio, et al.
Publicado: (2017)

Direct oral anticoagulants for unusual‐site venous thromboembolism
por: Riva, Nicoletta, et al.
Publicado: (2021)

Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
por: Masini, Marta, et al.
Publicado: (2023)

Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events
por: Poénou, Géraldine, et al.
Publicado: (2023)

Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism
por: López-Núñez, Juan J., et al.
Publicado: (2019)

Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism
por: Yhim, Ho-Young, et al.
Publicado: (2014)

Direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer
por: Planquette, Benjamin, et al.
Publicado: (2019)

Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis
por: Lopes, Luciane Cruz, et al.
Publicado: (2014)

Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register
por: Palareti, Gualtiero, et al.
Publicado: (2020)

FRI111 Venous Thromboembolism In Cushing Syndrome - A Call For Standardized Anticoagulation Regimen In Hypercortisolism
por: Minasyan, Mari, et al.
Publicado: (2023)

Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
por: Song, Andrew B, et al.
Publicado: (2019)

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
por: Ay, C, et al.
Publicado: (2019)

Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants
por: Weitz, Jeffrey I., et al.
Publicado: (2017)

The Use of Direct Oral Anticoagulants in the Management of Venous Thromboembolism in Patients With Obesity
por: Younis, Moustafa, et al.
Publicado: (2020)

The role of direct oral anticoagulants in venous thromboembolic disease in gynecologic cancer
por: Park, Jeong-Yeol
Publicado: (2019)

Arguments for Using Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism
por: Chiorescu, Roxana Mihaela, et al.
Publicado: (2021)

Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis
por: Tun, Han Naung, et al.
Publicado: (2022)

Comparison of effectiveness and safety of direct oral anticoagulants versus vitamin-k antagonists in elderly patients with atrial fibrillation: a systematic review and cost-effectiveness analysis protocol
por: Wang, Na, et al.
Publicado: (2020)

Current Opinion on the use of Direct Oral Anticoagulants for the Prophylaxis of Venous Thromboembolism among Medical Inpatients
por: Lee, Jane J, et al.
Publicado: (2021)

Efficacy of Direct Oral Anticoagulant into the Care of Venous Thromboembolism Related to Kumamoto Earthquake
por: Matsukawa, Mai, et al.
Publicado: (2018)

Efficacy and Safety of Direct Oral Anticoagulants for Risk of Cancer-Associated Venous Thromboembolism
por: Zeng, Jie, et al.
Publicado: (2019)

Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants
por: Kim, Sang-A, et al.
Publicado: (2019)

Direct Oral Anticoagulants vs. Vitamin-K Antagonists in the Elderly With Atrial Fibrillation: A Systematic Review Comparing Benefits and Harms Between Observational Studies and Randomized Controlled Trials
por: Shen, Nan-Nan, et al.
Publicado: (2020)

Impact of Age, Sex, and Renal Function on the Efficacy and Safety of Direct Oral Anticoagulants vs. Vitamin K Antagonists for the Treatment of Acute Venous Thromboembolism: A Meta-Analysis of 22,040 Patients
por: Zhou, Bo, et al.
Publicado: (2021)

Editorial: Venous thromboembolism and pregnancy
por: Tardy, Bernard, et al.
Publicado: (2022)

Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism
por: Prins, Martin H, et al.
Publicado: (2013)

Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017
por: Lutsey, Pamela L., et al.
Publicado: (2019)

Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence
por: García-Escobar, I., et al.
Publicado: (2020)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
por: Al-Ghafry, Maha, et al.
Publicado: (2022)

Safety and Effectiveness of Direct Oral Anticoagulants for the Treatment of Gastrointestinal Cancer-Associated Venous Thromboembolism
por: Ullah, Fauzia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2kgfdl4poiln8mve4sjvebv10h